The high invalidation rate for life science patents in China has created a headache for drug companies and a money-making opportunity for enterprising individuals
Shenzhen-based Transsion is a dominant market player in Africa, but a light IP portfolio might complicate its ambitious expansion plans
Designing a unique and striking app name and icon is crucial for developers keen to set their innovations apart from competitors. However, it is important to protect the app name and enforce your trademark rights to prevent others from profiting on the app’s success.
An inside look at Huawei’s patent buying strategy, TCL’s safeguards against over-investment, Baidu’s IP shift and much more from IPBC Shenzhen
As two of the world’s largest tech businesses aggressively grow their patent stockpiles a new entrant from China is the one to watch
Storm clouds are gathering over the most talked about company in the telecoms sector but as we embark on a new era of mobile technology, Huawei still enjoys a number of notable advantages.
The big stories from the IAM platform in February and March.
Regulations in the special economic zone once known primarily as a den of piracy will allow fast-track administrative injunctions and impose stiff penalties on repeat infringers
China’s healthcare sector is booming and while the patent system has developed considerably in recent years, pharmaceutical companies should still think carefully about how to protect their rights.
As the Chinese authorities continue to promote the rapid development of the country’s IP market, they are also investing more efforts into countering various forms of patent market abuse.
"The business places more and more scrutiny on patent spend, and asks the patent team to quantify the value proposition and return on investment,” says David Dutcher
CNIPA has promised to reduce examination times, but users are more concerned about quality. Agency's deputy director waves off the suggestion that 90% of its issued patents are 'junk'
The new IP tribunal shows that China is accepting its responsibilities as a world leader in IP policy, says the former US Federal Circuit chief judge.
With China emerging as a crucial market for the life sciences, it is crucial that those in the industry keep up with the swift pace of IP reforms and other changes – especially when it comes to enforcement.
After nine years of legal manoeuvring, the US chipmaker has won approval for its licensing practices in Japan. But in other parts of the region, antitrust doubts remain